NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis $5.58 -0.02 (-0.36%) As of 09:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immuneering Stock (NASDAQ:IMRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immuneering alerts:Sign Up Key Stats Today's Range$5.51▼$5.7250-Day Range$2.44▼$5.9552-Week Range$1.10▼$6.18Volume20,029 shsAverage Volume1.24 million shsMarket Capitalization$202.67 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingModerate Buy Company Overview Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Read More Immuneering Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreIMRX MarketRank™: Immuneering scored higher than 71% of companies evaluated by MarketBeat, and ranked 299th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuneering has only been the subject of 3 research reports in the past 90 days.Read more about Immuneering's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 7.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.04% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuneering has recently decreased by 5.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.04% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuneering has recently decreased by 5.45%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.37 News SentimentImmuneering has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Immuneering this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for IMRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have bought more of their company's stock than they have sold. Specifically, they have bought $334,318.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMRX Stock News HeadlinesNeedham & Company LLC Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)August 28 at 2:19 AM | americanbankingnews.comImmuneering Corporation: Ripping On A Questionable CatalystAugust 26 at 5:21 PM | seekingalpha.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)Immuneering Corporation Closes $25 Million Private Placement to Support Oncology Drug DevelopmentAugust 26 at 4:32 PM | quiverquant.comQImmuneering Announces Closing of $25 Million Private PlacementAugust 26 at 4:05 PM | globenewswire.comImmuneering signs supply deal with Lilly to test atebimetinib plus olomorasibAugust 25, 2025 | msn.comImmuneering stock soars on clinical supply deal with Eli LillyAugust 25, 2025 | za.investing.comImmuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On DipsAugust 25, 2025 | msn.comSee More Headlines IMRX Stock Analysis - Frequently Asked Questions How have IMRX shares performed this year? Immuneering's stock was trading at $2.20 at the start of the year. Since then, IMRX shares have increased by 154.5% and is now trading at $5.60. How were Immuneering's earnings last quarter? Immuneering Corporation (NASDAQ:IMRX) announced its earnings results on Wednesday, August, 13th. The company reported ($0.40) EPS for the quarter, meeting analysts' consensus estimates of ($0.40). When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Immuneering's major shareholders? Top institutional shareholders of Immuneering include Marshall Wace LLP (1.59%), Geode Capital Management LLC (0.64%), Bridgeway Capital Management LLC (0.27%) and Corient Private Wealth LLC (0.18%). Insiders that own company stock include Benjamin J Zeskind, Brett Matthew Hall, Peter Feinberg, Leah R Neufeld, Mallory Morales, Harold Eugene Brakewood and Diana Hausman. View institutional ownership trends. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuneering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings8/13/2025Today8/29/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMRX CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Immuneering$13.00 High Price Target$21.00 Low Price Target$8.00 Potential Upside/Downside+132.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-146.28% Return on Assets-117.22% Debt Debt-to-Equity RatioN/A Current Ratio3.70 Quick Ratio3.70 Sales & Book Value Annual Sales$320 thousand Price / Sales635.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book7.00Miscellaneous Outstanding Shares36,320,000Free Float28,002,000Market Cap$203.39 million OptionableNot Optionable Beta0.37 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IMRX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.